Everolimus for the treatment of advanced pancreatic ductal adenocarcinoma (PDAC)

Hani M. Babiker, Michael Karass, Alejandro Recio-Boiles, Sreenivasa R. Chandana, Ali McBride, Daruka Mahadevan

Research output: Contribution to journalArticlepeer-review

15 Scopus citations


Introduction: PDAC is a lethal malignancy with a clear unmet need; almost all patients fail 1st, 2nd, and 3rd line multi-agent cytotoxic chemotherapy. The mammalian target of rapamycin (mTOR) has been identified as a key signaling node enhancing tumor survival and drug resistance in PDAC; hence, it is considered a promising therapeutic target. Areas covered: We comprehensively reviewed the evidence from preclinical and phase I and II clinical trials, based on the authors’clinical experience and a PubMed, Cochrane library, Embase, and Google Scholar search everolimus + pancreatic cancer. Expert opinion: Everolimus has not demonstrated efficacy in PDAC; however, an mTOR inhibitor in combination with stroma-targeted therapies may be a promising area to explore in clinical trials.

Original languageEnglish (US)
Pages (from-to)583-592
Number of pages10
JournalExpert Opinion on Investigational Drugs
Issue number7
StatePublished - Jul 3 2019
Externally publishedYes


  • Everolimus
  • mTOR
  • pancreatic adenocarcinoma

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'Everolimus for the treatment of advanced pancreatic ductal adenocarcinoma (PDAC)'. Together they form a unique fingerprint.

Cite this